Literature DB >> 19596840

Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption?

Angela Spelsberg1, Anke Martiny, P S Schoenhoefer.   

Abstract

Mesh:

Year:  2009        PMID: 19596840     DOI: 10.1136/jech.2008.084939

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


× No keyword cloud information.
  5 in total

Review 1.  Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.

Authors:  Lilyana Amezcua; Flavia Nelson
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Authors:  Amy T Wang; Christopher P McCoy; Mohammad Hassan Murad; Victor M Montori
Journal:  BMJ       Date:  2010-03-18

3.  Chronological changes in Japanese physicians' attitude and behavior concerning relationships with pharmaceutical representatives: a qualitative study.

Authors:  Sayaka Saito; Kei Mukohara; Yasushi Miyata
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

4.  The Global Fund: why anti-corruption, transparency and accountability matter.

Authors:  Zhihao Chang; Violet Rusu; Jillian C Kohler
Journal:  Global Health       Date:  2021-09-18       Impact factor: 4.185

Review 5.  Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review.

Authors:  Melissa Mialon; Stefanie Vandevijvere; Angela Carriedo-Lutzenkirchen; Lisa Bero; Fabio Gomes; Mark Petticrew; Martin McKee; David Stuckler; Gary Sacks
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.